Creating the “Next Healthcare System”

Published Nov 12, 2018

Panel Explores the Game-Changing Potential of Digital Technologies to Transform Healthcare

 Barcelona, Spain—12 November 2018—ISPOR, the professional society for health economics and outcomes research, held a spotlight session this afternoon at ISPOR Europe 2018, “Healthcare X.0: Digital Technologies and Creation of Value” [IP4], that explored how digital technologies are creating the next generation healthcare system in Europe and beyond. Speakers for this session included:
  • Moderator: Andrew Rosner, MBA, Syneos Health, Toronto, ON, Canada
  • John Hernandez, PhD, Google Brain, San Francisco, CA, USA
  • John G. Singer, Wipro Limited, New York, NY, USA
  • Egge van der Poel, PhD, Erasmus University Medical Centre, Rotterdam, The Netherlands
  • Violeta Isabel Perez-Nueno, PhD, European Commission, Luxembourg
Digital technologies have the game-changing potential to create and deliver substantial improvements in healthcare. In fact, the very nature of healthcare valuation and delivery is being redefined with the rise of digital. These technologies also offer the opportunity for health economics and outcomes researchers to participate in the co-creation of the “next healthcare system.” The panel discussed an ambitious digital health initiative by the European Commission to create a Digital Single Market that seeks to design a Europe-wide ecosystem of data-driven healthcare. The panel examined issues from both a European and global perspective. Key themes that the panel anticipates impacting next generation healthcare included standardization and evidence rigor of digitally-enabled insights into outcomes measurement, transparency and reliability of digital data sources, value creation created by interoperability, and the impact of digitally-supported solutions. ISPOR is recognized globally as the leading professional society in HEOR and its role in improving healthcare decisions. ISPOR Europe 2018 is the leading HEOR conference in Europe and draws more than 5000 healthcare stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, and patient engagement organizations. Additional information on ISPOR Europe 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBarcelona.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×